Likewise, MCF7 cells, while representative of HR+ BC, do not model the full spectrum of BC subtypes, particularly TNBC or HER2+ disease, and lack the tumor microenvironment components that influence drug response in vivo (Neve et al., 2006; Holliday and Speirs, 2011). This evidence concerns the gene ERBB2 and breast cancer.